Ken Griffin Lyell Immunopharma, Inc. Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$1.13 - $1.88 $17,515 - $29,140	15,500 Added 596.15%	18,100 $24,000
Q2 2024 Aug 14, 2024	BUY	$1.3 - $3.01 $3,380 - $7,825	2,600 New	2,600 $3,000
Q4 2023 Feb 14, 2024	SELL	$1.39 - $2.35 $12,371 - $20,915	-8,900 Reduced 87.25%	1,300 $2,000
Q3 2023 Nov 14, 2023	BUY	$1.45 - $3.35 $14,355 - $33,165	9,900 Added 3300.0%	10,200 $14,000
Q2 2023 Aug 14, 2023	SELL	$1.89 - $3.86 $1,323 - $2,702	-700 Reduced 70.0%	300 $0
Q1 2023 May 15, 2023	SELL	$1.97 - $3.58 $3,349 - $6,086	-1,700 Reduced 62.96%	1,000 $2,000
Q4 2022 Feb 14, 2023	BUY	$2.78 - $8.09 $7,505 - $21,843	2,700 New	2,700 $9,000

121

142M

18.1K

200

Ticker LYEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 247,824,992
Market Cap $161M
Description
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.